Moreover, although midodrine significantly increased MAP and was associated with a numerical reduction in PRA that did not reach statistical significance, these hemodynamic changes did not translate into clinical benefit.
← all excerpts
Midodrine in patients with ACLF and ascites: When increasing blood pressure is not enough
1
—
—